Sweden's SOBI Q1 revenue slightly beats estimates on immunology and hematology strength

Swedish Orphan Biovitrum AB (publ)

28/04/2026 07:22

Overview

Sweden biopharma firm's Q1 revenue rose 11%, slightly beating analyst expectations

Q1 EBIT beat analyst estimates

Company completed acquisition of Arthrosi Therapeutics in Q1

Outlook

Sobi expects 2026 revenue to grow at low double-digit percentage at CER

Company anticipates 2026 adjusted EBITA margin in the mid 30s percentage of revenue

Sobi says 2026 outlook is unchanged from previous guidance

Result Drivers

HAEMATOLOGY SALES - Revenue in Haematology rose 24% at CER, mainly due to higher sales of Altuvoct and Doptelet

IMMUNOLOGY SALES - Immunology revenue increased 24% at CER, driven by higher sales of Gamifant and Kineret

STRATEGIC PORTFOLIO GROWTH - Revenue from the strategic portfolio grew 55% at CER

Company press release: ID:nWkr90Ryd8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
SEK 7.18 bln
SEK 7.15 bln (5 Analysts)
Q1 EBIT
Beat
SEK 1.87 bln
SEK 1.79 bln (5 Analysts)
Q1 Adjusted Free Cash Flow
SEK 1.13 bln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Swedish Orphan Biovitrum AB (publ) is SEK450.00, about 12.9% above its April 27 closing price of SEK398.60

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)